“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware...
How do you obtain the best possible patient care available? On this week's Few & Far Between podcast, host Chris O'Brien welcomes patient advocacy...
"We work with hundreds of patients a month, helping them understand their own medical history and then tracking what happens to them in the...